42098-25-9

Usage

Uses

Used in Pharmaceutical Synthesis:
5-chloro-1-Methyl-4-nitro-1H-pyrazole is used as a key intermediate in the synthesis of pharmaceuticals for its unique attributes and versatile core structure. Its chloro, methyl, and nitro substituents contribute to the compound's physicochemical properties and biological activities, making it a valuable component in the development of new drugs.
Used in Agrochemical Synthesis:
In the agrochemical industry, 5-chloro-1-Methyl-4-nitro-1H-pyrazole is utilized as a building block for the creation of bioactive compounds with potential applications in crop protection and pest control. Its unique structure and substituents allow for the development of novel agrochemicals with improved efficacy and selectivity.
Used in Scientific Research:
5-chloro-1-Methyl-4-nitro-1H-pyrazole serves as a subject of study in scientific research, where its physical and chemical properties, toxicity, and biological activity are investigated. Understanding these aspects can provide insights into its potential applications and help guide the development of new compounds with specific therapeutic or pesticidal properties.
Used in Drug Design and Optimization:
5-chloro-1-Methyl-4-nitro-1H-pyrazole is employed in drug design and optimization processes, where its unique attributes and versatile core structure can be leveraged to create new pharmaceutical agents with improved potency, selectivity, and safety profiles. Its chloro, methyl, and nitro substituents can be modified to fine-tune the compound's properties and enhance its therapeutic potential.
Used in Chemical Synthesis Education:
5-chloro-1-Methyl-4-nitro-1H-pyrazole can be utilized as a teaching tool in chemical synthesis courses, providing students with hands-on experience in working with complex organic compounds and understanding the principles of medicinal chemistry and agrochemistry.

InChI:InChI=1S/C4H4ClN3O2/c1-7-4(5)3(2-6-7)8(9)10/h2H,1H3

Upstream product

• 3994-50-1 1-methyl-4-nitropyrazole 
• 2075-46-9 4-nitro-1H-pyrazole 
• 67-72-1 hexachloroethane 

Downstream Products

• 1338718-97-0 C₁₅H₁₈N₄O₄ 
• 1428573-85-6 benzaldehyde O-6,6-difluoro-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepan-4-yloxime 
• 1338718-11-8 tert-butyl 3-(4-amino-1-methyl-1H-pyrazol-5-yl)phenylcarbamate 
• 1428573-74-3 3-fluoro-5-(4-methoxybenzyloxy)-1-(1-methyl-4-nitro-1H-pyrazol-5-yl)azepane 

Relevant academic research and scientific papers

Synthesis and Biological Profiling of Pyrazolo-Fused 7-Deazapurine Nucleosides

A series of 8-substituted 1-methyl-1,4-dihydropyrazolo[3′,4′:4,5]pyrrolo[2,3-d]pyrimidine (methylpyrazolo-fused 7-deazapurine) ribonucleosides have been designed and synthesized. Two synthetic approaches to the key heterocyclic aglycon 7, (i) a six-step c

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.

NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Compound of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, X, Y and G are as defined in the description, and their use in the manufacture of medicaments.

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.

Kinase inhibitor, and preparation and application of kinase inhibitor

The invention provides a compound shown as a formula (I), or a stereoisomer, a tautomer, nitrogen oxide, metabolite, a prodrug, pharmaceutically acceptable salt or solvate of the compound, and application of the compound to preparing drugs or drug compositions for treating Pim kinase-mediated diseases.

ORGANIC COMPOUNDS

The present invention relates to novel PDE2 inhibitory compounds of Formula I as described above, their use as pharmaceuticals and pharmaceutical compositions comprising them.

FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes furo- and thieno-pyridine carboxamide compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for in

CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.